An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
Incyte Corporation
Incyte Corporation
University of Miami
OHSU Knight Cancer Institute
National Cancer Centre, Singapore
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation